- Home
- GLRE vs AGMB Comparison
GLRE vs AGMB Comparison
Compare GLRE & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLRE | AGMB |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | Cayman Islands | Belgium |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.9M | 652.5M |
| IPO Year | 2007 | 2024 |
Fundamental Metrics
Financial Performance| Metric | GLRE | AGMB |
|---|---|---|
| Price | $15.48 | $14.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | ★ 130.1K | 85.9K |
| Earning Date | 05-05-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.00 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $729,777,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.86 |
| P/E Ratio | $86.22 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $8.75 |
| 52 Week High | $19.39 | $17.82 |
Technical Indicators
Market Signals| Indicator | GLRE | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 42.33 | 49.68 |
| Support Level | $14.57 | $11.37 |
| Resistance Level | $17.05 | $14.19 |
| Average True Range (ATR) | 0.37 | 0.91 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 24.55 | 19.29 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About AGMB AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.